EPDR1: A Potential Drug Target and Biomarker (G54749)

Target Name: EPDR1

NCBI ID: G54749

EPDR1

EPDR1: A Potential Drug Target and Biomarker

Erythropoietin (EPO) is a hormone produced by the kidneys that regulates the production of red blood cells in the body. It is essential for maintaining the health and function of the immune system, and its levels are closely monitored by the body. One of the EPs is called EPDR1, which has been identified as a potential drug target and biomarker for several diseases.

The EPDR1 gene is located on chromosome 17 and encodes a protein known as EPDR1. This protein plays a critical role in the production and function of EPs. It is a key regulator of the growth and differentiation of hematopoietic stem cells, which are responsible for the production of all blood cells in the body.

EPDR1 has been shown to be involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its role in these diseases has led to its potential as a drug target.

One of the ways that EPDR1 has been linked to cancer is its role in the development of leukemia, a type of cancer that affects the bone marrow and blood cells. Studies have shown that EPDR1 is often overexpressed in leukemia cells, which can lead to the inhibition of the immune system and the development of cancer.

EPDR1 has also been linked to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to contribute to the symptoms of these diseases.

EPDR1 has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and lupus. These conditions are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage.

Despite these promising findings, more research is needed to fully understand the role of EPDR1 in disease. One way to do this is through the development of RNA-based diagnostic tools, such as microarray analysis, to measure the expression of EPDR1 in different tissues and cells. This can help identify potential drug targets and biomarkers for diseases associated with EPDR1.

Another approach is to use EPDR1 as a therapeutic target. By inhibiting the activity of EPDR1, researchers may be able to reduce the production of EPs and potentially slow down or reverse the progression of diseases associated with EPDR1.

In conclusion, EPDR1 is a protein that has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand its role in these conditions and to develop effective treatments.

Protein Name: Ependymin Related 1

Functions: Binds anionic lipids and gangliosides at acidic pH

The "EPDR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPDR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets